Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study
European Journal of Neurology · 2025-03 · 32 (3)
DOI: 10.1111/ene.70095 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift European Journal of Neurology, online erschienen am 04.03.2025. Verfasst von Anders Myhre Vaage und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Akershus University Hospital, Lørenskog, Norway. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ALS Norway, Helse Sør-Øst RHF.
Abstract (Originalsprache)
Background
Dyslipidemia is common in amyotrophic lateral sclerosis (ALS). Statin use has been associated with both favorable and poor prognoses. We assessed whether statin use affects ALS survival.
Methods
We linked four Norwegian health surveys (1972–2003) with mandatory national registries to obtain information on premorbid health, ALS diagnosis, and death. Using the Norwegian Prescribed Drug Registry, we identified participants who had dispensed statins pre‐ and post‐diagnosis. We first compared pre‐diagnosis statin discontinuation rates between ALS patients and matched controls. Flexible parametric models were then fitted to estimate the relationship between statin use and survival time in ALS, using restricted mean survival time and hazard ratio (HR) as effect measures.
Results
A total of 524 patients (43% female) with ALS were included. Mean time from ALS diagnosis to death or end of study was 2.0 (SD 2.1) years. A substantial proportion of statin users (21%) discontinued statins during the year leading up to diagnosis. This group was characterized by poorer ALS prognosis compared to those adhering to statins and were included as statin users in our analysis. After adjusting for sex, age, birth year, riluzole use and premorbid smoking status, body mass index, and total cholesterol levels, statin use was not associated with ALS survival. The estimated mean survival difference comparing statin users to non‐users was 0.74 (95% CI −5.98 to 7.47) months, corresponding to a HR of 0.97 (95% CI 0.77–1.23).
Conclusion
Statin use was not associated with ALS survival, suggesting that statins should not routinely be discontinued in ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Akershus University Hospital, Lørenskog, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Community Medicine and Global Health, University of Oslo, Oslo, Norway.
- Department of Physical Health and Ageing, Norwegian Institute of Public Health, Oslo, Norway.
ORCID-Profile: Anders Myhre Vaage, Trygve Holmøy, Jesper Dahl, Haakon E Meyer, Ola Nakken
Förderung
- ALS Norway
- Helse Sør-Øst RHF
Zitieren
APA
Vaage, A. M., Holmøy, T., Dahl, J., Stigum, H., Meyer, H. E., & Nakken, O. (2025). Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study. European Journal of Neurology, 32(3). https://doi.org/10.1111/ene.70095
Vancouver
Vaage AM, Holmøy T, Dahl J, Stigum H, Meyer HE, Nakken O. Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study. European Journal of Neurology. 2025;32(3). doi:10.1111/ene.70095
BibTeX
@article{Vaage2025,
author = {Vaage, Anders Myhre and Holmøy, Trygve and Dahl, Jesper and Stigum, Hein and Meyer, Haakon E and Nakken, Ola},
title = {Statin Use and Amyotrophic Lateral Sclerosis Survival: A Population‐Based Cohort Study},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {3},
doi = {10.1111/ene.70095}
}
EUVIMED